Completed more than 1 month/cycle (28 days) of chemotherapy for pancreas cancer
Patient on an immunosuppressive systemic treatment, such as steroids, in the past 2 years.
Other cancer diagnosis requiring treatment within two years
History of allergic reactions related to the drugs (Nivolumab, Cyclophosphamide, GM-hetastarch, corn, dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin), yeast or any other component of the GVAX vaccine) in this study.
Patients receiving growth factors within the last 14 days.
Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, psychological, immune or other medical conditions.
Pregnant or breastfeeding.
Have known history of infection with HIV, hepatitis B, or hepatitis C.
Unwilling or unable to follow the study schedule for any reason.
Presence of tissue or organ allograft, regardless of need for immunosuppression (including corneal allograft)
Squamous pancreatic cancer or adenosquamous pancreatic cancer with malignant squamous cells \>30%
Clareo Health | GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
